Cormorant Asset Management, LP Eagle Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $9.92 Million - $12.2 Million	-200,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $9.32 Million - $12.1 Million	200,000	200,000 $11.9 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.